Zobrazeno 1 - 10
of 44
pro vyhledávání: '"George H. Lowell"'
Publikováno v:
Vaccine. 35:713-715
We previously reported a 2011/12 study in elderly showing that immunization with the universal influenza vaccine candidate, M-001, three weeks before administering trivalent influenza vaccine (TIV) enhanced seroconversion of Hemagglutination Inhibiti
Publikováno v:
Vaccine
The feasibility of developing a prophylactic vaccine against SARS was assessed by comparing the immune responses elicited by immunizing mice with a recombinant SARS spike glycoprotein (S-protein) formulated with different adjuvants, given by differen
Autor:
Tomas Leanderson, Jon Hartas, Michael R. Batzloff, Mark R. Davies, Gregory L. White, Michael F. Good, George H. Lowell, Huaru Yan, David S. Burt
Publikováno v:
The Journal of Infectious Diseases. 192:1450-1455
Infection with group A streptococcus (GAS) may result in a number of clinical conditions, including the potentially life-threatening postinfectious sequelae of rheumatic fever and rheumatic heart disease. As part of the search for a vaccine to preven
Autor:
Sonya L. Cyr, Sophie Chabot, Martin Plante, Brian J. Ward, Angela Brewer, David S. Burt, George H. Lowell
Publikováno v:
Vaccine. 23:1374-1383
Protollin-MV is a vaccine produced by mixing split measles virus (MV) antigen with the novel adjuvant Protollin (Neisseria meningitidis outer membrane proteins non-covalently complexed with Shigella flexneri 2a lipopolysaccharide). Intranasal immuniz
Autor:
Sonya L. Cyr, David S. Burt, Nathalie Bellerose, Francine Allard, George H. Lowell, Taff Jones
Publikováno v:
Vaccine. 22:3691-3697
Protollin is a novel adjuvant comprising Proteosomes non-covalently complexed with LPS. Intranasal immunization of mice with Protollin combined with detergent-split influenza antigens (HA) or recombinant influenza hemagglutinin (rHA) enhanced serum I
Autor:
Gregory L. White, Louis Fries, Colin Gelder, Rob Lambkin, John S. Oxford, David S. Burt, George H. Lowell
Publikováno v:
International Congress Series. 1263:661-665
FluINsure™ is an intranasal influenza vaccine containing inactivated antigens with the Proteosome™ adjuvant. Preclinical and human data have shown a good safety profile and immune responses in both the systemic compartment and mucosal compartment
Autor:
Sonya L. Cyr, Nathalie Bellerose, George H. Lowell, Joelle Gauthier, Taff Jones, Francine Allard, Martin Plante, David S. Burt, Steven P. Tran
Publikováno v:
Vaccine. 21:3706-3712
The potential for enhancing the immunogenicity of recombinant (baculovirus-derived) influenza hemagglutinin (rHA) was investigated by comparing the immune responses elicited in mice by an intranasal (i.n.) rHA formulated with Proteosomes, with those
Autor:
Noutcheka St-Félix, Francine Allard, Krikor Torossian, Greg White, Joelle Gauthier, David S. Burt, Taff Jones, Martin Plante, George H. Lowell
Publikováno v:
Vaccine. 20:218-225
The immunogenicity of a mucosally delivered subunit influenza vaccine was assessed in mice. Split influenza virus vaccine (sFlu) was formulated with proteosomes (Pr-sFlu), administered intranasally, and the induced immunity was compared with the resp
Autor:
Thomas C. VanCott, Robert W. Kaminski, John R. Mascola, Vaniambadi S. Kalyanaraman, Nabila M. Wassef, Carl R. Alving, J.Terry Ulrich, George H. Lowell, Deborah L. Birx
Publikováno v:
The Journal of Immunology. 160:2000-2012
Because mucosal surfaces are a primary route of HIV-1 infection, we evaluated the mucosal immunogenicity of a candidate HIV-1 vaccine, oligomeric gp160 (o-gp160). In prior studies, parenteral immunization of rabbits with o-gp160 elicited broad neutra
Autor:
Ofra Axelrod, Shoshana Frankenburg, Robert McMaster, George H. Lowell, Sidney Klaus, Charles L. Greenblatt, Esther Aboud Pirak, S. Kutner
Publikováno v:
Vaccine. 14:923-929
Two peptides representing predicted T-cell epitopes of gp63, a major surface glycoprotein of the parasite Leishmania major, were used in vaccines tested in a murine model of cutaneous leishmaniasis. Either subcutaneous or intraperitoneal immunization